Pre-order Enquiry
Request Free Sample
Healthcare
Aerospace & Defence
Agriculture
Automations
Chemicals & Advanced Materials
Food & Beverages
Information & Communication Technology
Oil & Gas
Power & Energy
Phosphoglucomutase (PGM 1) Deficiency - Market Insights, Epidemiology and Market Forecast-2028’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of IPF in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.
The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Phosphoglucomutase (PGM 1) Deficiency from 2017 to 2028 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.
Geography Covered
• The United States
• EU5 (Germany, France, Italy, Spain and the United Kingdom)
• Japan
Study Period: 2017-2028
Phosphoglucomutase (PGM 1) Deficiency - Disease Understanding and Treatment Algorithm
The DelveInsight PGM-1 deficiency market report gives the thorough understanding of the PGM1 by including details such as disease definition, cause, symptoms, pathophysiology, and diagnostic trends. It also provides treatment algorithms and treatment guidelines for etiology in the US, Europe, and Japan.
Phosphoglucomutase (PGM 1) Deficiency Epidemiology
The Phosphoglucomutase (PGM 1) Deficiency epidemiology division provide the insights about historical and current patient pool and forecasted trend for every eight major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (total prevalent cases, prevalence of PGM1 deficiency based on clinical manifestations and congenital malformations, and prevalence based on severity) scenario of PGM1 deficiency in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom), and Japan from 2017-2028.
According to DelveInsight, total prevalent population of Idiopathic PGM1 deficiency in 7MM markets was found to be 2593 in 2017.
Phosphoglucomutase (PGM 1) Deficiency Drug Chapters
This segment of the PGM1 deficiency encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, and the latest news and press releases.
The current strategies for the treatment of PGM-1 deficiency primarily encompass galactose administration along with other off-label symptomatic medications to ensure the overall reduction of associated disease complications. In general, the current mainstays for the PGM-1 deficiency treatment includes dietary supplementation of sugar along with other cardiotonic, complex carbohydrates, hydrocortisone and symptomatic medications to make the affected individuals clinically comfortable. Furthermore, physical, occupational, and speech therapy are additional management modalities that impart clinical benefits to the PGM-1 deficient individuals. Currently two drugs are under development for the treatment of Phosphoglucomutase 1 (PGM1) deficiency. CERC-801 (Cerecor Inc.) an ultra-pure, oral, crystalline formulation of D-galactose and ORL-1G-D-galactose (Orpha Labs) are into eraly phase of clinical development.
Phosphoglucomutase (PGM 1) Deficiency Market Outlook
The PGM1 deficiency market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a through detail of market trend of marketed drug and pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the market of Idiopathic Pulmonary Fibrosis in 7MM was found to be USD 10.86 million in 2017.
Phosphoglucomutase (PGM 1) Deficiency Drugs Uptake
This section focusses on the rate of uptake of the potential drugs in the market during the study period from 2017-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Phosphoglucomutase (PGM 1) Deficiency Report Insights
• Patient Population
• Therapeutic Approaches
• Pipeline Analysis
• Market Size and Trends
• Market Opportunities
• Impact of upcoming Therapies
Phosphoglucomutase (PGM 1) Deficiency Report Key Strengths
• 10 Year Forecast
• 7MM Coverage
• Epidemiology Segmentation
• Drugs Uptake
• Highly Analyzed Market
• Key Cross Competition
Phosphoglucomutase (PGM 1) Deficiency Report Assessment
• Current Treatment Practices
• Unmet Needs
• Detailed Pipeline Product Profiles
• Market Attractiveness
• Market Drivers and Barriers
Key Benefits
• This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving Phosphoglucomutase (PGM 1) Deficiency market
• Organize sales and marketing efforts by identifying the best opportunities for Phosphoglucomutase (PGM 1) Deficiency market
• To understand the future market competition in the Phosphoglucomutase (PGM 1) Deficiency market.
The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Phosphoglucomutase (PGM 1) Deficiency from 2017 to 2028 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.
Geography Covered
• The United States
• EU5 (Germany, France, Italy, Spain and the United Kingdom)
• Japan
Study Period: 2017-2028
Phosphoglucomutase (PGM 1) Deficiency - Disease Understanding and Treatment Algorithm
The DelveInsight PGM-1 deficiency market report gives the thorough understanding of the PGM1 by including details such as disease definition, cause, symptoms, pathophysiology, and diagnostic trends. It also provides treatment algorithms and treatment guidelines for etiology in the US, Europe, and Japan.
Phosphoglucomutase (PGM 1) Deficiency Epidemiology
The Phosphoglucomutase (PGM 1) Deficiency epidemiology division provide the insights about historical and current patient pool and forecasted trend for every eight major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (total prevalent cases, prevalence of PGM1 deficiency based on clinical manifestations and congenital malformations, and prevalence based on severity) scenario of PGM1 deficiency in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom), and Japan from 2017-2028.
According to DelveInsight, total prevalent population of Idiopathic PGM1 deficiency in 7MM markets was found to be 2593 in 2017.
Phosphoglucomutase (PGM 1) Deficiency Drug Chapters
This segment of the PGM1 deficiency encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, and the latest news and press releases.
The current strategies for the treatment of PGM-1 deficiency primarily encompass galactose administration along with other off-label symptomatic medications to ensure the overall reduction of associated disease complications. In general, the current mainstays for the PGM-1 deficiency treatment includes dietary supplementation of sugar along with other cardiotonic, complex carbohydrates, hydrocortisone and symptomatic medications to make the affected individuals clinically comfortable. Furthermore, physical, occupational, and speech therapy are additional management modalities that impart clinical benefits to the PGM-1 deficient individuals. Currently two drugs are under development for the treatment of Phosphoglucomutase 1 (PGM1) deficiency. CERC-801 (Cerecor Inc.) an ultra-pure, oral, crystalline formulation of D-galactose and ORL-1G-D-galactose (Orpha Labs) are into eraly phase of clinical development.
Phosphoglucomutase (PGM 1) Deficiency Market Outlook
The PGM1 deficiency market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a through detail of market trend of marketed drug and pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the market of Idiopathic Pulmonary Fibrosis in 7MM was found to be USD 10.86 million in 2017.
Phosphoglucomutase (PGM 1) Deficiency Drugs Uptake
This section focusses on the rate of uptake of the potential drugs in the market during the study period from 2017-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Phosphoglucomutase (PGM 1) Deficiency Report Insights
• Patient Population
• Therapeutic Approaches
• Pipeline Analysis
• Market Size and Trends
• Market Opportunities
• Impact of upcoming Therapies
Phosphoglucomutase (PGM 1) Deficiency Report Key Strengths
• 10 Year Forecast
• 7MM Coverage
• Epidemiology Segmentation
• Drugs Uptake
• Highly Analyzed Market
• Key Cross Competition
Phosphoglucomutase (PGM 1) Deficiency Report Assessment
• Current Treatment Practices
• Unmet Needs
• Detailed Pipeline Product Profiles
• Market Attractiveness
• Market Drivers and Barriers
Key Benefits
• This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving Phosphoglucomutase (PGM 1) Deficiency market
• Organize sales and marketing efforts by identifying the best opportunities for Phosphoglucomutase (PGM 1) Deficiency market
• To understand the future market competition in the Phosphoglucomutase (PGM 1) Deficiency market.
Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
